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INTRODUCTION 
 
Systemic Lupus Erythematosus is a chronic progressive autoimmune 
disease with multisystem manifestation. 
 
 The underlying abnormalities in systemic lupus erythematosus is due to 
the production of a number of pathogenic autoantibodies and immune 
complexes and to an inability to suppress and clear them. The disease can 
present in a wide variety of forms, degrees, and manifestation, ranging from 
relatively mild cutaneous and joint involvement to lethal cardiac, renal and 
cerebral involvement. 
   
 Systemic lupus erythematosus commonly presents in young and middle 
aged woman who comprise upto 90% of all systemic lupus erythematosus 
sufferers. Systemic lupus erythematosus is three times more common in blacks 
than in other races and Asians display an increased incidence of systemic lupus 
erythematosus against Caucasians. 
 
 
 
 
  
HISTORY 
In 1852 Cazenave and Chausit5 were the first to use the new famous 
name Lupus erythematosus and to describe a number of systemic manifestation 
of this condition. 
 In 1939 Rose and Pillsbury31 described disseminated multiorgan 
involvement in this chronic progressive disease of unknown etiology. Their 
report was considered the beginning of modern history of systemic lupus 
erythematosus. 
 In 1941 Klemperer and coworker19 published their article on Pathology 
of Disseminated Lupus erythematosus again emphasizing the importance of 
vasculitis as a central feature of systemic lupus erythematosus. 
 In 1964 Halmay and Ludwig16 described a case of deep band shaped 
white grayish coloured keratitis with hyaline granular aspect apparently with 
involvement of descement membrane.  This was associated with uveitis in 
patient with lupus whose cutaneous manifestation were simultaneous with 
ocular findings. 
 In 1993 Varga and Wolf39 described the case of systemic lupus 
erythematosus with extensive impairment of the CNS and bilateral transient 
keratoendothelitis responsive to topical and systemic corticosteroids. 
 
  
PATHOPHYSIOLOGY 
 
 Systemic lupus erythematosus is a dysfunction in immunoregulation in 
an individual genetically predisposed to have such dysregulation triggered by 
an environment agent such as microbe or a drug or other chemical. The 
immunopathology is related primarily to B lymphocyte hyperactivity although 
T cell abnormalities are seen as well. Numerous antibodies and immune 
complexes that cause specific tissue damage are produced, however not all 
antibodies are pathogenic. 
 
 Additionally other immunoregulatory mechanisms are abnormal in 
systemic lupus erythematosus including T – lymphocyte numbers and function 
and the inability to clear antibodies and immune complexes.                             
Auto antigen – autoantibodies and immune complexes formed in systemic lupus 
erythematosus patients are deposited at certain loci in “target tissues” and can 
lead to subsequent complement activation, inflammatory cell chemotaxis to the 
site of the immune complex. Release of proteolytic and collangenolytic 
enzymes from these cells result in tissue digestion and damage. 
 
 A genetic predisposition with high concordance of disease in 
monozygotic twins as compared to dizygotic twins and an increased frequency 
of family members affected with systemic lupus erythematosus. There are 
  
associations with class II HLA genes including HLADR2 and HLADR3 
particularly HLA-DRB-I *0301 allele and DQA –I * 0501 allele. These HLA 
regions exert certain effect on certain autoantibodies. Complement genes C4A, 
C4B also play important role. Genetic studies show that the defect is in the 
region of chromosome 6 were the putative immune response genes is located. 
  
 Systemic lupus erythematosus vasculitis often shows nonspecific 
pathological changes. Findings include fibrinoid necrosis of small vessels and 
capillaries and deposition of immunoglobulin and complement. Lupus 
anticoagulants may initiate clotting within blood vessels. 
 
 In the eye, the immune complexes deposit in the vascular endothelium of 
conjuctiva, sclera, choroids, ciliary body and retina, alter the tissue structure 
and compromise function. Deposit can also develop in the basement membrane 
of the ciliary body and conjuctiva. While most patients with retinopathy have 
systemic disease, retinopathy can also occur independently of systemic flare-
ups. Systemic lupus erythematosus patients with retinopathy have higher 
morbidity risk.  
       
 
 
  
ENVIRONMENTAL FACTORS  
VIRAL INFECTION : Systemic lupus erythematosus is caused by an 
inappropriate immune response to viral infection, namely Type C virus of 
reoviridae family. This virus has particular tropism for thymus cells. The virus 
incorporates the genome into the host genome. On multiplication the altered 
DNA provoke antibodies against itself. Thus thymic dysfunction and disturbed 
immunoregulation, molecular mimicry plays important role. 
 
UVRADIATION  
 
DRUG: Hydrazine Procainamide Methyldopa Isoniazid 
  
HORMONAL FACTORS: 
  More in females and more in pregnant women. Estrogen enhances the 
disease and testosterone suppresses it. 
 
 
 
 
 
 
  
SYSTEMIC MANIFESTATION OF  
SYSTEMIC LUPUS ERYTHEMATOSUS  
 
The various systemic manifestation divided into constitutional renal 
dermatologic, neurological, ophthalmic, and others. 
 
CONSTITUTIONAL SYMPTOMS :  
 
Prominent constitutional symptoms include fever, malaise, arthralgia, 
myalagia, headache, loss of appetite and weight. 
Skin findings include the typical malar butterfly rash, discoid lesions, 
non specific crythematous maculopapular rash, and cutaneous vasculitic lesion.  
 
RENAL MANIFESTIONS : 
 
 This is the most common manifestation.36 All patients of systemic lupus 
erythematosus have deposits of immunoglobin, in glomeruli, one half of 
patients have clinical nephritis defined by persistent protenuria.15 Most patient 
are asymptomatic except those with edema of nephrotic syndrome. Urine 
analysis shows haematuria and protenuria. They present with mesangial or 
mildfocal glomerulonephritis. Patients with high proportion of sclerotic 
  
glomeruli on biopsy, usually have serum creatinine of more than 265 micromols 
per litre are unlikely to respond to immunosuppressive therapy. 
 
DERMATOLOGICAL MANIFESTATIONS: 
 Dermatological features play a prominent role in the diagnostic scoring 
system and are second most common manifestation.36  
The pathognomonic lupus or butterfly rash across the nose and cheeks 
occurs in some 30% of patients with systemic lupus erythematosus. Discoid or 
disc shaped skin lesion may also occur in systemic lupus erythematosus and 
discoid lupus erythematosus. They begin as erythematosus macules, expand to 
plaques but always retain their discrete coin shape. They occur on extensor 
surface of arms and on neck, face and scalp. They occur in 15 to 30% of patient 
with systemic lupus erythematosus. Photosensitivity rash is also typical with 
systemic lupus erythematosus with sunburn of extreme severity. Livedo 
reticularis is seen in systemic lupus erythematosus patients with frank vasculitis 
or in those individuals with anticardiolipin antibodies. Alopecia is another 
manifestation. Other manifestations are raynaud phenomenon, oral nasal or 
other mucous membrane ulceration and telengiectasias may occur. 
 
 
 
  
NEUROLOGICAL MANIFESTATIONS : 
Neurological manifestations of lupus are seen in 25 to 75% of patients 
and can involve all parts of nervous system. The neurological manifestations 
were similar in systemic lupus erythematosus and connective tissue disorder 
and a positive correlation is seen with antiphospholipid antibodies and 
anticardiolipid antibodies. The various manifestations are personality disorder, 
seizures, psychosis, stroke and migrainous headache.  
 
PREGNANCY AND LUPUS : 
Pregnancy and lupus is complicated by high rate of spontaneous 
abortions and stillbirth and flare up of the disease with resulting fetal loss and 
fetal growth retardation. Congenital lupus includes discoid lupus and congenital 
heart block often detected in-utero. 
 
DRUG INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS  
The drugs implicated in systemic lupus erythematosus are procainamide, 
hydralizne, isoniazid, chlorpromazine, pencillamine, practolol, methyl dopa, 
oral contraceptive pills and propylthiouracil. Patients with drug induced 
systemic lupus erythematosus are woman presenting with polyarthritis, pleuritis 
or Pericarditis. Anti histone  anti bodies are usually present. 
 
  
SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHER 
AUTOIMMUNE DISEASES: 
The following autoimmune diseases are associated namely autoimmune 
thyroid disease, hereditary C1Q deficiency, SS-systemic sjogren syndrome. 
 
 
 
 
 
 
 
 
 
 
 
 
  
OCULAR MANIFESTATIONS OF                           
SYSTEMIC LUPUS ERYTHEMATOSUS 
 
EXTERNAL: 
 KERATOCONJUCTIVITIS SICCA 
 CONJUCTIVITIS 
 SUPERFICIAL PUNCTATE KERATITIS  
 INTERSTITIAL KERATITIS 
 EPISCLERITIS AND SCLERITIS 
 
RETINAL MANIFESTATION: 
 COTTON WOOL SPOTS  
 HAEMORRAGES 
 BRANCH RETINAL VEIN OCCLUSION 
 CENTRAL RETINAL VEIN OCCLUSION  
 CENTRAL RETINAL ARTERY OCCLUSION 
 RETINALVASCULITIS 
 PROLIFERATIVE RETINOPATHY 
 
 
 
  
 
CHOROIDAL MANIFESTATION: 
 ISCHEMIC CHOROIDAPATHY  
 RETINAL PIGMENT EPITHELIAL CHANGES  
 CHOROIDAL VASCULITIS 
 
NEURO OPHTHALMIC AND ORBITAL MANIFESTATION: 
 OPTIC NEURITIS  
 ISCHEMIC OPTIC NEUROPATHY  
 PSEUDOTUMOUR CEREBRI 
 MIGRAINE  
 HEMIANOPIA  AND AMAUROSIS 
 VISUAL HALLUCINATIONS  
 GENICULOCALCARINE BLINDNESS 
 PUPILLARY AND OCULOMOTOR DISTURBANCE  
 INTERNUCLEAR OPHTHALMOPLEGIA  
 ORBITAL PSEUDOTUMOUR 
 ORBITAL MYOSITIS 
 
 
  
          The most common ocular manifestation of systemic lupus erythematosus 
is keratoconjuctivitis sicca with or without xerostomia35 occurs in 
approximately 25% of patients. Keratoendothelitis causing transient corneal 
edema has been noted.41 The lesions responded well to Quinacrine 
hydrochloride. Diffuse anterior or nodular scleritis closely may mimic the level 
of systemic activity in the disease. Periorbital edema is a rare manifestation of 
the disease. 
 
LIDS AND CONJUNCTIVA:  
 Patients can present with non specific blepharitis without scarring. Other 
lesions are lid plaque, lid scarring, symblepharon formation. They responded 
well to topical steroids but in patient with more extensive bilateral involvement 
these have recurred as treatment was reduced. Chemosis may be the initial 
presentation in systemic lupus erythematosus patients.    
 
CORNEAL MANIFESTATIONS : 
 
  The corneal manifestations of systemic lupus erythematosus are by large 
confined to epithelium. Peripheral ulcerative keratitis have been reported in 
patients with systemic lupus erythematosus. Sicca syndrome is quite common 
.Gold and his associates found a 6.5% incidence of keratitis in an outpatient 
  
population of systemic lupus erythematosus patients. Spaeth studied that 88% 
of systemic lupus erythematosus patients revealed superficial punctate keratitis 
with fluorescein corneal staining.33 Schrimer test were normal in these patients 
.Therefore the superficial punctate keratitis seen in these patients are due to dry 
eye states or due to the disease process itself is under investigation. A case of 
bilateral deep segmental interstitial keratitis, a rare finding has also been 
reported.29 
 
SCLERAL INVOLVEMENT: 
 
Recurrent episcleritis, scleritis may be the initial presentation in systemic 
lupus erythematosus. Scleritis mimics the level of systemic disease and it 
resolves with adequate control of systemic disease and it will not respond to 
topical therapy. 
 
UVEAL INVOLVEMENT:  
 Uveitis is an uncommon manifestation. Patient presents with pain, 
photophobia and diminished vision. On examination there is corneal edema, 
flare, cells, keratic precipitates and fibrinous membrane. Response is good with 
steroids hence vision loss prevented.  
 
 
 
  
RETINAL MANIFESTATIONS : 
 
          Retinal involvement in systemic lupus erythematosus is quite common, 
second only to keratoconjunctivitis sicca. The reported prevalence has varied 
greatly between patients in precorticosteroid era and ambulatory systemic lupus 
erythematosus patients with better control of the disease. The appearance and 
disappearance of retinal lesions in patients with systemic lupus erythematosus 
parallels the systemic clinical course. Effective control of systemic disease is 
associated with dramatic decrease in retinal lesions.13 Moreover systemic lupus 
erythematosus patients with retinopathy have decreased survival rate compared 
to systemic lupus erythematosus patients without retinopathy.34 Patients are 
usually asymptomatic and rarely complain of loss of vision and scotomas. 
 
RETINAL VESSEL SHEATHING : 
They are focal fluffy white cuffing which develop around long stretched 
vessels. They may be continuous more around the veins than arteries.  
Pathogenesis: 
Circulating leucocytes must slow down and adhere to the vascular 
endothelium. This is brought about by the adhesion molecules. Initial adhesion 
by L selectin and carbohydrate slows the leucocyte. Once tethered they 
stimulate P selectin and E selectin, adhere to the carbohydrate moiety called 
  
addresins in the vascular endothelium. Firm adhesions of the leucocyte by 
interaction of its integrin receptors latch the cell on the vessel wall. This results 
in activation of leucocytes and flattening of cell. Binding of cell adhesion 
molecules on the endothelium initiates migration. These cells migrate out of the 
endothelium into extracellular matrix and bind to beta-integrins in the extra 
cellular matrix and form perivascular cuffing. 
 
COTTON WOOL SPOTS: 
          The classic finding in lupus retinopathy is cotton wool spots. They 
represent areas of microvascular occlusion. They may be isolated or surrounded 
by haemorrage. They are due to focal areas of ischemia due to interruption of 
axoplasmic flow in the nerve fibre layer of retina, resulting in accumulation of 
axoplasmic material and swelling of nerve fibre layer, probably due to 
occlusion of precapillary arteriole or end arteries by thrombus or inflammatory 
cells. FFA correspond to focal areas of nonperfusion .Histology reveals focal 
swelling of nerve fibre layer with cytoid bodies .DD: diabetes, hypertension, 
ischemic retinal vein occlusion. 
         The pathological finding in lupus retinopathy includes infiltration of 
vessel wall with fibrillar material causing vascular constriction and widespread 
hyaline thrombus formation. Although focal areas of vessel wall infiltrates are 
seen, the vessel wall themselves are free of inflammatory cells. This is not a 
  
true vasculitis. This type is associated with active systemic disease and CNS 
lupus.  
 
ARTERIAL OCCLUSION: 
             It is rare for lupus retinopathy. More common in patients with 
antiphospholipid antibodies. Features result in central retinal artery occlusion, 
extensive capillary nonperfusion and retinal neovascularisation may occur. This 
is associated with active systemic disease and CNS lupus. 
 
VENOUS OCCLUSION: 
            Systemic lupus erythematosus is not a venous disease. Arterial 
occlusion secondarily causes venous stasis and engorgement of veins with a 
picture resembling central retinal vein occlusion. Acquired protein S deficiency 
is also reported in systemic lupus erythematosus. 
 
VASODISRUPTION: 
Intra retinal haemorrages are frequent finding in lupus retinopathy. 
Microaneurysm formation, vascular leakage, retinal edema, preretinal 
haemorrage can also occur. Studies have proven that increased intraretinal 
haemorrage is proportional to increased risk of mortality.  
 
 
  
ISCHEMIC SEQULAE: 
          Features of hypertensive retinopathy like arteriolar attenuation, arterio 
venous crossing changes, intra retinal haemorrage hard exudates can occur. 
Sometimes systemic lupus erythematosus patients may present with 
bilateral mottled retinas with spots or clumps of pigments which may resemble 
those patients with retinitis pigmentosa. These may be due to vasoocclusive 
phenomenon. 
 
        The data has indicated that if retinal vasculitis exists in a patient with 
systemic lupus erythematosus, then the renal, pulmonary and cardiovascular 
status of the patient  will be the next to suffer the consequences of immune 
complex vasculitis as illustrated by el-Asrar and Associates. 
CHORDOIAL INVOLVEMENT: 
Choroidopathy is much less common in systemic lupus erythematosus as 
compared with retinopathy. A case of bilateral serous detachment has been 
reported in systemic lupus erythematosus. Transudation of fluid is seen through 
bruch’s membrane and the retinal pigment epithelium which appears to be 
affected by ischemia, may be due to immune complex deposits in bruch 
membrane. The presence of antineuronal antibodies found in serum and CSF of 
systemic lupus erythematosus patients has led them to speculate the existence 
of anti retinal pigment epithelial antibodies. Sometimes choroidal infarction 
  
with occlusive vascular disease leads to irreversible blindness - “ELSCHNIG 
SPOTS.” Immunopathological studies have shown extensive deposits of 
immune complexes in the choroid probably because of profuse blood flow. 
Others include extensive mononuclear cell inflammatory infiltrate .Although 
more extensive changes are seen in lupus in choroids than retina they are 
always subclinical. 
 
NEURO OPHTHALMIC INVOLVEMENT: 
The neuro ophthalmological manifestations have been reviewed by 
LESSEL.23 The optic nerve and chiasma may be involved in systemic lupus 
erythematosus most likely by an ischemic process. Anterior or posterior 
ischemic optic neuropathy or a picture similar to optic neuritis has been 
reported. Pathological findings include demyelination, axonal necrosis or a 
combination of both. These findings are associated with antiphospholipid 
antibodies.  
Disc edema in lupus may be secondary to hypertension, central retinal 
vein occlusion, focal ischemic disease, increased intra cranial tension, or 
transverse myelitis. A clinical picture similar to pseudotumour cerebri has also 
been reported.  
Retrochiasmal visual problems in lupus include geniculocalcarine 
blindness, homonymous hemianopia, visual hallucinations and transient 
  
amaurosis. Patients with systemic lupus erythematosus are prone to migraine 
and amaurosis in systemic lupus erythematosus and respond better to nifidipine 
suggesting a vascular etiology. Manifestation consistent with Miller Fisher 
Syndrome in systemic lupus erythematosus (ataxia, areflexia, ophthalmoplegia) 
has also been reported. 
The pupillary abnormalities in systemic lupus erythematosus are 
secondary to brain stem lesions. Painful ophthalmoplegia reversed by steroids 
are seen in systemic lupus erythematosus patients .Diplopia is transient 
phenomenon often with vertigo can be seen suggesting vestibulobasilar 
insufficiency .Unilateral internuclear ophthalmoplegia is well documented with 
systemic lupus erythematosus. Isolated ptosis and isolated sixth nerve palsies 
are also reported. 
 
OTHER OPHTHALMIC INVOLVEMANT: 
 
Orbital involvement mimics pseudotumour cerebri and there is a good 
response to steroids. Orbital myositis manifesting with proptosis, pain with 
external ocular movements restriction have been noted. Reports of concomitant 
development of Brown syndrome have also been noted. Often this is the cause 
of vertical diplopia in patients with systemic lupus erythematosus.  
 
  
SYSTEMIC INVESTIGATIONS 
ROUTINE BLOOD INVESTIGATIONS 
 Total count  
 Red blood cell count  
 Differential count 
 Erythrocyte Sedimentation Rate  
 Findings may include anaemia, leucopenia, lymphopenia,  
thrombocytopenia and Erythrocyte sedimentation rate will be raised. 
 Serum Creatinine  
 Blood urea  
 Bleeding Time  
 Clotting Time  
 Prothrombin Time  
 
URINE ALUBUMIN, SUGAR , DEPOSITS: 
This is to rule out renal pathology Albuminuria is more common in 
systemic lupus erythematosus patients. 
 
IMMUNOLOGICAL TESTS; 
 Antinuclear antibodies are elevated in 95% of patients with systemic 
lupus erythematosus. However their absence does not rule out the diagnosis. 
  
Anti Nuclear Antibodies can be seen in other systemic diseases. But antibodies 
to double stranded and anti smith antibodies to polypeptides that complex with 
certain species of nuclear RNA are quite specific for systemic lupus 
erythematosus. Disease activity in systemic lupus erythematosus can be 
correlated with high titres of Anti Nuclear Antibodies and low complement 
levels and with high titers of cryoglobulins by the Raji cell assay .Some of the 
antibodies found in systemic lupus erythematosus are as follows. 
 
Specificity antigen   clinical importance and comments 
                         
Nuclear                            multiple antigens detected: sensitive when 
Hep-2 or WIL-2 cells used; used quite non specific. 
 
          NativeDNA                       highly specific for systemic lupus erythematosus 
seen in 70% of lupus patients, associated with 
nephritis and disease activity 
 
Denatured DNA                high titers in systemic lupus  
erythematosus; low titers in other diseases 
  
Sm (smith)                        highly specific for systemic lupus  
erythematosus seen in 50% of patients 
  
Histones                            more common in drug induced systemic  
lupus erythematosus (95%) 
Nuclear                             seen in systemic lupus erythematosus highest  
Ribonucleoprotein   titers in multiple connective tissue disease 
 
Ro(SSa)                             seen in primary sjogren syndrome and  
systemic lupus erythematosus 
 
La(SSb)                             seen in primary sjogren syndrome and  
systemic lupus erythematosus 
 
Nucleolar                          seen in scleroderma, primary sjogren and  
systemic lupus erythematosus 
 
Phospholipid cardiolpin    seen in systemic lupus erythematosus and  
other diseases ;gives false positive VDRL 
 
          Clotting factors                lupus anticoagulants, cause prolonged PTT  
     associated with venous and arterial thrombosis 
Endothelial surface          may contribute to thrombosis  
Antigens 
  
 
Platelet surface antigen    associated with thrombocytopenia 
 
Erythrocyte surface          occasionally associated with haemolysis 
antigens                            
Lymphocyte surface        may be associated with leucopenia  
antigens                           and abnormal T cell function 
 
Neuronal antigens           high titers are correlated with diffuse CNS  
Lupus                                                                                               
 
 
ELISA 
Recent study using enzyme linked immunosorbent assay has shown that 
the level of plasma cell free Fc gamma receptor III (FcgammaRIII) also may 
increase significantly in patients with systemic lupus erythematosus. Also using 
ELISA, antibodies to human fibronectin (anti-fn) are detected in the sera of 
34% of patients with systemic lupus erythematosus. There is an association 
with serum anti fibronectin antibodies and disease activity in systemic lupus 
erythematosus. 
 
 
 
  
 
INTERLEUKINS 
Soluble interleukin (IL-2)receptor (CD25) and soluble CD27 and CD 30 
molecules are elevated in the serum of patients with systemic lupus 
erythematosus prior to an exacerbation of clinically evident disease activity. 
More over serum levels of interleukin-6 (IL-6) and interferon gamma have been 
found to be increased in patients with systemic lupus erythematosus. 
Systemic lupus erythematosus patients may also show abnormality in 
their cerebrospinal fluid. There is local synthesis of oligoclonal IgG in 25% of 
cases and worsening of blood barrier function. 
 
 
 
 
 
 
 
 
  
OCULAR INVESTIGATIONS 
 
Clinical tests for dry eye  
 There is no single “gold standard” test for detecting dry eye disorders. 
Schirmer I test is done without anaesthesia using Whatman filter paper ≠41. 
Room temperature and humidity must be consistent from test to test. The time 
of administration of the last drop and the time of testing are recorded. The test 
is done under ambient light conditions. Only one pair of tests should be done on 
a given day.  
  The test is done without touching the paper directly with the finger to 
avoid contamination of skin oil. The paper is placed at the junction of the 
middle and lateral one third of the lower eye lid. The patient is told to look 
forward and blink normally while a strip is placed in the right eye followed by 
the left eye. The strips are removed after 5 min and the amount of wetting is 
recorded in millimeters. The amount of wetting less than 10mm is considered to 
be positive.  
Basal Schirmer test is done after anaesthetising with a drop of 
proparacaine. Schirmer strips are placed and the wetting is recorded. Amount of 
wetting less than 5mm is considered to be positive.  
  
Augumented Schirmer test: Schirmer strips are placed and the nasal 
mucosa is irritated near the middle meatus with swab sticks.  Reflex tearing is 
present in non-Sjogren’s syndrome and absent in Sjogren syndrome.    
 
Tear break up time  
 Break up time may measured invasively by using fluorescein (FBUT) or 
non-invasively using a keratometer or a xeroscope (NBUT). Fluorescein 
breakup time may not be reproducible and may not reliably reflect disease. 
Fluorescein strips are wet with a standardised drop of non-preserved saline 
solution and the strip is touched to the interior palpebral conjunctiva. Subjects 
are asked to blink several times and asked to move their eyes around thoroughly 
mix the fluorescein with the tear film. Patients are asked to first close and then 
open their eyes. The time from opening of the eyes to the appearance of the first 
dry spot is measured three times and the mean is recorded. A 10 second 
reference value is taken and <10 seconds is taken as abnormal.  
 Non invasive breakup time requires a keratometer or a xeroscope. Break 
up times are shorter using a keratometer as compared to xeroscope.   
 
 
 
  
Rose Bengal staining  
 Rose Bengal stains areas of ocular surface where the tear film is 
discontinuous. It is commercially available as impregnated strips. Classically, 
the Van Bijsterveld grading system has been used assigning a grade (0-3) based 
on density of staining of the temporal and nasal conjunctiva and cornea of each 
eye.  
 Examination by light passed through green filter is recommended after 
Rose Bengal staining.  
 
Tear film osmolarity  
 This test has high sensitivity and specificity when used as a single test 
and hence is taken as a “gold standard”. However, it is unable to distinguish 
evaporative and tear deficient dry eye. The technique requires determining 
osmolarity on basal tears and the avoidance of reflex tearing. Commercially 
osmometers are available. But the process still needs standardization and an 
experienced technician.  
Other tests are:  
 Fluorescein clearance test  
 Lissamine Green staining  
 Tear ferning  
 Conjunctival impression cytology  
  
 Brush cytology  
 Lysozyme assay  
 Lactoferrin assay 
 Tear protein analysis   
Slit Lamp examination  
Indirect ophthalmoscope  
Anterior chamber tap  
Vitreous tap  
 
Fundus fluorescein angiography  
Aim:  To evaluate retinal perfusion  
 To detect retinal neovascularsation  
 Confirm lupus choroidopathy  
 
Findings:  
• Areas of poor capillary bed perfusion usually around disc and 
macula21  
• Abrupt termination of retinal arteries and arterioles  
• Focal areas of capillary drop outs – cotton wool spot, irregular retinal 
vessel caliber  
  
• Marked stasis with segmentation of blood column and dye      
extravasations in veins  
• Neo vascular tufts seen as points of dye leakage  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DIAGNOSIS 
 
 The diagnosis of systemic lupus erythematosus is based on a 
combination of clinical and laboratory criteria, which have varied over the past 
decade. Two of the most useful systems are those proposed by Cohen and 
associates (and accepted by the American Rheumatism Association) and by 
Hahn. 
 
American rheumatism Association criteria   
 
 The revised 11 diagnostic criteria proposed by the American 
Rheumatism Association (ARA) are accepted widely. The diagnosis of SLE can 
be made if four of these criteria are met, serially or simultaneously, during any 
interval of observation. Ocular disorder is not one of the criteria.20,26    
 
Criteria for classification of SLE 
Criterion  Sensitivity (%) Specificity (%) 
Malar rash: flat or raised erythematosus 
rash over malar eminences  
57 96 
Discoid rash: raised, erythematosus 
patches with adherent keratoic scaling 
and follicular plugging  
18 99 
  
Photosensitivity: skin rash by history or 
physician observation caused by 
unusual reaction to sunlight  
43 96 
Oral or nasopharyngeal ulcers: usually 
painless  
27 96 
Nonerosive arthritis: involving two or 
more peripheral joints  
86 37 
Serositis: pleuritis (by history or if rub 
or effusion are present) or pericarditis 
(electrocardiographic changes, rub, or 
pericardial effusion)  
56 86 
Renal disorder: persistent proteinuria or 
cellular casts  
51 94 
Neurological disorder: seizures or 
psychosis in the absence of metabolic 
disease or offending drug  
20 98 
Hematological disorder:anemia, 
leucopenia, lymphopenia, or 
thrombocytopenia  
59 89 
Immunological disorder: positive lupus 
erythematosus cell preparation, anti-
DNA antibodies, anti-Sm antibodies, or 
false-positive serology for syphilis  
85 93 
Antinuclear antibody: abnormal titer in 
the absence of known offending drugs 
99 49 
 
 
 
  
Hahn’s criteria 
 
Anti Nuclear Anti Bodies (1:5) + score of 7 points 
 Points  
Butterfly rash  2 
Rash biopsy findings compatible with SLE 2 
Polyarthritis  2 
Serositis  2 
Glomerulonephritis biopsy findings compatible with SLE 2 
LE cells 2 
Rash compatible with SLE, not biopsy-proved 1 
Clinical nephritis, no biopsy 1 
Organic brain syndrome  1 
Localizing neurologic signs  1 
Alopecia  1 
Raynaud’s phenomenon  1 
Nail-bed capillary abnormality  1 
Arthralgia  1 
Fever 1 
Retinal cytoid bodies  1 
  
Polymyositis  1 
Myocarditis  1 
Hemolytic anemia  1 
Leucopenia  1 
Thrombocytopenia  1 
Lymphadenopathy 1 
Positive results on direct Coombs’ test  1 
False-positive STS results  1 
Antibodies to DNA 1 
Hypergammaglobulinemia  1 
Hypocomplementuria  1 
Circulating anticoagulant 1 
 
 
 
 
 
 
 
 
  
TREATMENT 
 Therapy for the ocular surface manifestations of systemic lupus 
erythematosus is based on successful control of the underlying disease, as well 
as local therapy for the keratitis and tear deficiency. The usual therapy for sicca 
syndrome (tear replacement, soft contact lenses, punctal occlusion) may 
produce both symptomatic and objective improvement. Topical steroid therapy 
maybe a useful adjunct to systemic steroid therapy in the treatment of the 
scleritis. The retinopathy resolves only with successful control of the 
underlying systemic disease. Immunosuppression, primarily with 
corticosteroids, is the mainstay of therapy. Immunosuppressive drugs like 
cyclosporine A 2.5 mg to 5mg/kg/BW 2 times daily are also given. Other 
immunosuppressants used are tacrolimus, methotrexate, azathioprine and 
cyclophosphamide. Recently mycophenolate mofetil, which inhibits purine 
synthesis, has been tried.  
 Laser photocoagulation for proliferative retinopathy, using criteria from 
studies on diabetes and branch retinal vein occlusions, is believed to be 
beneficial. However, there is a report of a case of anterior segment ischemia in 
a patient after panretinal photocoagulation for proliferative lupus retinopathy. 
Although the mechanism of ischemia was unclear, the authors suggested 
avoiding undue pressure with the contact lens during laser photocoagulation, 
  
keeping the treatment sessions short, and avoiding the use of retrobulbar 
anesthesia will help to prevent this complication. Flat retinal new vessels are 
treated by argon laser spots 200-500µm for 0.1 sec. Panretinal photocoagulation 
500µm for 0.1 sec 1500-2000 burns in 2to 3 settings. Finally, surgical 
intervention may be necessary in patients with vitreous hemorrhage and 
tractional retinal detachment.  
Systemic treatment  
 Many patients with systemic lupus erythematosus have relatively mild 
disease, and they will lead relatively normal lives with conservative therapy in 
the form of adequate rest and nutrition, use of a skin-protective sunscreen when 
avoidance of sun exposure is impossible, and use of salicylates and other 
nonsteroidal antiinflammatory agents for control of arthralgia, myalgia, low-
grade serositis, and mild constitutional symptoms. Antimalarial therapy (e.g., 
hydroxychloroquine sulfate) may be the next step employed in arthralgia and 
arthritis control or in therapy for cutaneous lesions or mild anterior segment 
ocular inflammatory lesions if non-steroidal antiinflammatory agents have not 
been effective. One must be careful to watch for the possibility of development 
of a drug-induced retinopathy. Patients can test themselves with an Amsler grid.  
 Severe manifestations of systemic lupus erythematosus require therapy 
with systemic corticosteroids. Disabling constitutional symptoms and articular, 
cutaneous, and other systemic manifestations of the disease unresponsive to the 
  
aforementioned conservative therapy should be treated with the minimum daily 
dose of corticosteroid required for adequate control of disease activity. 
Alternate-day steroid therapy is ineffective in the treatment of systemic lupus 
erythematosus, and most patients respond considerably better to divided daily 
doses (e.g., two or three times a day) than to single morning doses of 
corticosteroid. Severe disease affecting the central nervous, cardiovascular, 
pulmonary, or renal system may require initial high-dose (60-300 mg of 
prednisone/day) steroid therapy, tapered as soon as clinical improvement 
warrants it. In tapering daily prednisone dosage from the 60mg/day level, a 
useful rule of thumb is to decrease the dosage by 10 percent every 3 days until 
40mg/day is reached; then the tapering should be slower.  
 Systemic lupus erythematosus renal or CNS crisis is usually treated with 
high-dose intravenous steroid therapy (1-2 gm of methylprednisolone/day for 3-
6 days) in conjunction with high-dose oral steroid (100-300 mg of 
prednisone/day). Combination corticosteroid-cytotoxic therapy may be helpful 
in cases of severe systemic lupus erythematosus and in cases in which the 
systemic corticosteroids cannot be tapered below toxic levels without 
exacerbations of clinical disease. Cyclophosphamide may be the most effective 
cytotoxic agent studied for this purpose. Plasmapheresis for lupus crisis is also 
under investigation. Dapsone has yielded good therapeutic results in certain 
forms of systemic lupus erythematosus.  
  
REVIEW OF LITERATURE 
 
1. Ophthalmic manifestations in Asian patients with systemic lupus 
erythematosus Yap EY, Au Eong KG, Fong KY, Howe HS, Boey ML. Cheah 
WM Feng PH.  
Singapore   Med Journal, 1998 Dec; 39(12) : 557-9. 
 A study conducted on 70 Asian patients with systemic lupus 
erythematosus from tertiary rheumatology unit to ophthalmology Department.  
 70 patients were included in the study. There were 66 females (94%) and 
4 males (6%) the mean age of patients was 32.9 yrs (9-67). 5 patients (7%) had 
ophthalmic symptoms while 65(93%) were asymptomatic. Eighty-three eyes of 
45 patients had abnormal schrimers test. 27 of these eyes of 17 patients also had 
concomitant rose Bengal staining of the cornea and the conjunctiva. Seventeen 
eyes of 9 patients had retinal vascular lesions. Fourteen of these eyes had mild 
microangiopathic retinopathy with BCVA of 6/12 or better and 3 had retinal 
vaso occlusive disease with BCVA worse than 6/12. 28 eyes of 14 patients had 
cataract and 3 eyes of 2 patients had raised intraocular pressure. 12 eyes of 7 
patients had BCVA worse than 6/12 because of optic neuropathy (4 eyes), 
Posterior subcapsular cataract (4 eyes), Retinal vaso occlusive disease (3 eyes) 
and phthisis bulibi (1 eye). None had any eyelid lesion, extraocular motility 
disorder or retrochiasmal disorder of vision.  
  
2. Retinal Disease in patients with systemic lupus erythematosus 
Osmau Ushiyama, Keiko Ushiyama Syuichi Koarada, Yoshifumi Tada Noriaki 
Suzuki Akihide Ohta, Shinji Oono Kohei Nagasawa.  
Ann. Rheumatology Dis 2000; 59: 705-708.  
A cross sectional study was made in 69 patients with systemic lupus 
erythematosus. The incidence retinopathy was young in 7/69 patients (ie) 10% 
of patients. The finding included vasculitis, cotton wool spots, hard exudates all 
which was considered to reflect vascular damage. The patients with retinopathy 
had higher levels of serum Creatinine than the patients without retinopathy 
(p<0.01).  
 
3. Ocular manifestation of systemic lupus erythematosus in children. 
A1 – Mayouf SM, Al – Hemidan AI. 
Saudi Med J.2003 Sep; 24(9): (964-6).  
 52 consecutive children (45 females) with systemic lupus erythematosus 
completed evaluation. The mean ages of patients were 11.3 years. 18 patients 
(34.6%) had ocular manifestation seven patients had abnormal schrimers test (2 
bilateral, 5 unilateral). Five patients (4 unilateral, one bilateral) had retinal 
vascular lesions. One patient had bilateral iridocyclitis. 3 patients had unilateral 
optic neuropathy and 11 patients had visual field defects (4 bilateral, 7 
unilateral). 
  
4. Neuro Ophthamological manifestations of systemic lupus erythematosus 
in Asian patients. 
Teoh SC, Yap EY, Au Eong KG.  
Clinic experiment ophthalmology 2001Aug: 29(4) 213-6. 
 To report 8 patients diagnosed as systemic lupus erythematosus who 
presented with a variety of neuro ophthamological complications. The most 
common manifestation was that of optic neuropathy and eye movement 
abnormalities. Ophthalmologist may need to consider the diagnosis of systemic 
lupus erythematosus in young woman who present with a recent onset of neuro 
ophthalmologic symptoms and signs. 
 
5. Unusual eye manifestations in systemic lupus erythematosus patients. 
Drosos AA, Petris CA, Petroutsos GM, Moutsopoulos HM. 
Clinic Rheumatology 1989 Mar; 8(1): 49-53. 
112 of patients with systemic lupus erythematosus were reviewed. 4 
cases of unusual ocular manifestation are described. We found that anterior 
uveitis is not an uncommon manifestation of systemic lupus erythematosus and 
physician must be aware of it during patient evaluation since it can be treated 
without serious visual loss. Optic neuritis is uncommon in systemic lupus 
erythematosus and visual loss may be permanent despite therapy. 
 
  
6. Systemic lupus erythematosus and the eye. 
Quan Dong Nguyen, C. Stephen Foster.  
IOC – Volu 38(1) 1998; Pg 33-36. 
 The diagnosis of systemic lupus erythematosus can be made if 4 of the 
11 criteria by American Rheumatism Association are met, serially or 
simultaneously during any interval of observation. Ocular disorder is not one of 
the criteria. 90% of systemic lupus erythematosus patients are women with 
usual age of onset between the ages 15 and 45. The most common ocular 
manifestation of systemic lupus erythematosus, Keratoconjuctivitis sicca with 
or without xerostomia, Occurs in 25% patients. Retinal involvement in systemic 
lupus erythematosus is quite common second only to Keratoconjuctivitis sicca. 
 
7. Prominent ocular findings as an early manifestation and of systemic 
lupus erythematosus.  
Ashish. M.Mehta MD., Thomas E Frane M.D. 
JPOS volume 35(2) 1998 Mar to Apr 114-115. 
 Unusual for ocular manifestation to precede with initial presentation of 
systemic disease. Gold and his colleagues showed 6.6% incidence of superficial 
keratitis and 1.6% uveitis (location unspecified).  
 
 
  
8. Corneal staining in systemic lupus erythematosus 
Spaeth GL: 
N Eng J. Med 276 1186/1987  
Spaeth in a study of systemic lupus erythematosus patients hospitalised 
at National Institute of ophthalmology stated that 88% had superficial punctate 
keratitis with fluorescein corneal stain. He reported that schrimer test were 
normal in some of these patients and therefore the issue of whether the 
superficial punctate keratitis seen in systemic lupus erythematosus is always 
truly the result of sicca syndrome or in fact due to corneal epithelial damage is 
unclear. Patient also exhibits punctate keratitis unrelated to dry eye status. 
 
9. External ocular finding in lupus erythematosus: a clinical and immuno 
pathological study. 
Peggy Frith, S M Burge, P R Millard, F Wonjnarowska   
British Journal Ophthalmology 1990, 74, 163-167. 
 A selected group 18 patients with systemic lupus erythematosus were 
examined for dryness of eyes. It was found in 2 of 11 patients. The five patients 
had recurrent episcleritis. More than half of the patients had ocular 
manifestation. Ocular features can occur early and may be sufficiently 
characteristic to suggest the diagnosis of lupus erythematosus. 
 
  
10. Retinopathy in systemic lupus erythematosus. 
James Coppeto, Simmons Lessell.  
Arch Ophthalmol- vol 95, May 1977. (797-799) 
 Reported 32 years old black women with systemic lupus erythematosus 
went rapidly blind due to severe bilateral Retinal vasculitis. The mechanisms 
appeared to be total arrest of retinal circulation by thrombosis of most retinal 
vessels including major arteries. 
 
11. Optic Neuropathy in Systemic Lupus Erythematosus  
Douglas A. Jabs, Neil R. Miller, Steven A. Newman.  
Arch Ophthalmol 1986; 104: (564-568). 
 Reported 7 cases of optic neuropathy in systemic lupus erythematosus 
visual outcome varied, but improvement occasionally occurred following 
treatment with corticosteroids. The clinical picture was variable and could 
present as acute retrobulbar optic neuritis, ischemic optic neuropathy, or slowly 
progressive visual loss. All cases were due to vasco-occlusive disease in small 
vessels of the optic nerves.  
 
 
 
 
  
AIM OF THE STUDY 
 
 To determine the spectrum and prevalence of ocular manifestation of 
systemic lupus erythematosus.  
 To identify potentially sight threatening lesions in ocular systemic 
lupus erythematosus.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
 
 The study was carried out at Government Rajaji Hospital Madurai. A 
standardized ophthalmic examination on Madurai patients with systemic lupus 
erythematosus referred from the Dermatology Department and Rheumatology 
Department from Madurai were included in the study.  The study was carried 
out prospectively and all ophthalmic examinations were carried out.  
 
 Relevant patient data recorded name, age, complaints, laboratory 
investigation reports including blood sugar, urea, serum creatinine urine 
albumin, total count, differential count, erythrocyte segmentation rate, bleeding 
time, clotting time, electrocardiogram, red blood cell count, Hemoglobin and 
Anti double stranded DNA results were recorded. Relevant ocular, family 
history and ocular complaints noted.  
 
 Ocular examination was carried in the routine manner using bright torch 
light using focal illumination, Binocular loupe and slit lamp examination was 
carried out for all cases.   
 
  
 The eyebrows, lids conjunctiva sclera, lacrimal system were closely 
studied. Tear film level, tear break up time, schrimer strip application, stained 
corneal examination was done in all cases. Tear film level of less than 0.3mm, 
tear break up time of less than 10seconds and schrimer strip less than 10mm 
were considered to be abnormal. Degree of dry eye status was noted. Cornea 
was checked for any opacities, punctate keratitis and interstitial keratitis. 
  
 Iris for any signs of iritis, iris atrophy, lens for any opacities were noted 
down. Corneal sensation was tested.  
 
Visual acuity, intraocular pressure measurement using schiotz tonometer, 
fields by Bjerrum screen, recording was also done for all patients. Refraction 
and appropriate glass correction given. Fundus examination with a direct 
ophthalmoscope and indirect ophthalmoscope was done to rule out retinal 
central and peripheral lesions.  
  
Retinopathy was defined as the presence of any of the following lesions; 
haemorrhages, vasculitis (Sheathing of retinal arterioles and /or venules or 
vascular tortuosity), cotton wool spots, papilloedema, optic atrophy, or retinal 
detachment according to the report of Stafford- Brady et al. In addition to these 
findings, we also included hard exudates unless the patients had essential 
  
hypertension or diabetes mellitus, because they were considered to be the result 
of deposition of exudated lipids or proteins form the degenerated ocular nerves 
or from vessels with hyperpermeability. Retinal lesions considered to be caused 
by hypertension (that is, not caused by Systemic Lupus Erythematosus), 
arteriosclerosis, or diabetes mellitus, were excluded.  
  
Renal disease was defined according to 1982 ACR criteria: persistent 
proteinuria (>0.5g/day or >3+) or cellular casts, or both. In addition, a raised 
serum creatinine level (normal >84µmol/l) was also included in the index. The 
data were analysed statistically by proportion test and Wilcoxon signed Rank 
Test.  
 
All findings were entered in the proforma for further analysis.  
 
  
 
 
 
 
 
 
  
OBSERVATIONS AND RESULTS 
Total No: of Patients – 33 
Total No: of eyes examined – 66. 
 During this period of study from January 2004 to January 2006, the total 
Number of systemic lupus erythematosus patients reported to Ophthalmology 
Department was 33. The total No: of females were 31 and there were 2 males. 
1. Age Distribution  
Table 1 
Age No of patients Percentage 
1-10 0 - 
11-20 7 21.2% 
21-30 18 54.55% 
31-40 7 21.2% 
Above 40 1 9.09% 
 
The youngest female reported was 11 years of age. 
 Out of 33 patients examined 7(21.2%) patients were in the age group of 
1-20 years and 18(54.55%) patients were in the age group of 21-30 years and   
7( 21.2%) patients were in the age group 30-40 years. One case of above forty 
years of age was reported in this study. 
 
  
2. Sex distribution: 
Table 2 
 No .of 
Patients 
No. of 
Percentage 
Comparative 
Study 
Males 2 6.06% 6% 
Females 31 93.9% 94% 
 
 In this study 31(93.9%) patients were females and 2(6.06%) patients 
were males. 
3. Ocular Manifestation in Systemic lupus erythematosus 
Table 3 
Ocular 
Manifestation 
No of Patients Percentage 
Present 21 63.63% 
Absent 12 36.36% 
 
 Out of 33 patients in study group, 21(63.63%) patients had some 
manifestation in the eyes where as 12(36.36%) patients had no manifestation. 
Their ocular examination was normal. 
 
 
  
4. Ocular Symptoms in Systemic lupus erythematosus 
Table 4 
Symptoms No of Patients Percentage 
Symptomatic 3 9.09% 
Asymptomatic 30 90.9% 
 
 Out of 33 patients only 3(9.09%) patients complained of ocular 
symptoms. 2 patients had complaints of decreased vision and irritation and one 
patient complained of floaters. The rest 30 (90.9%) patients were 
asymptomatic. 
 
5. Abnormal Schrimer’s and Systemic lupus erythematosus: 
Table 5 
Schrimer’s test  No of Patients Percentage 
Abnormal  9 27.27% 
Normal 24 72.73% 
 
 Out of 33 patients 9(27.27%) patients. (6 Bilateral and 3 unilateral) had 
abnormal schrimer test. Associated changes of tear film level, tear break up 
time were also seen. 27.27% of patients had abnormal schrimer test. 
 
 
  
Various studies showing abnormal schrimer : 
 
Various studies showing abnormal schrimer in systemic lupus erythematosus 
are tabulated  
 
TABLE 6 
 
Studies Percentage 
YAP EY & others 64.2% 
Peggy Frith 22% 
Steinberg Ad et al 25% 
Present Study 27.27% 
AlMayouf SM et al 13% 
 
6. Keratitis and Systemic lupus erythematosus: 
TABLE 7 
Keratitis   No of Patients Percentage 
Present 4 12.12 
Absent  29 87.88 
 
 
 4 (12.2%) patients of keratitis were found out of 33 patients. All the 4 
patients had punctate superficial epithelial erosion. All the 4 patients had 
inferior superficial punctate epithelial erosion. No case of interstitial keratitis 
and peripheral ulcerative keratitis were reported.  
  
 
7. Comparison of keratitis and abnormal schrimer 
TABLE 8 
Schrimer test 
Keratitis 
Normal Abnormal 
Absent 23 6 
Present 1 3 
 
 All keratitis were in the inferior part of cornea. Out of the 4 cases of 
keratitis, 3 patients had abnormal schrimer and one had normal schrimer. Out of 
23 patients who had normal schrimer only one case of keratitis was reported. 
8.Uveitis and Systemic lupus erythematosus 
Table 9 
Uveitis    No of Patients Percentage 
Present 1 3.03 
Absent  32 96.97 
 
 Uveitis is seen only in one(3.03%) patient which resolved with steroids. 
Patients presented with keratic precipitates, flare, cells with fibrinous 
membrane at pupillary margin unilaterally.  
 
  
 
9. Visual acuity and Systemic lupus erythematosus :  
TABLE 10 
Visual acuity   No of Patients Percentage 
6/12 – PL 4 12.12 
6/6 – 6/12 29 87.88 
 
 7 eyes of 4(12.12%) patients had visual acuity of less than 6/12. 
Posterior subcapsular cataract was found in 6 eyes of 3 patients. Visual acuity 
was diminished in 2 eyes due to  optic neuritis  and in 4 eyes due to retinal 
vasculitis. One patients had episcleritis with refractive error. 
10. Intraocular pressure, orbit and adnexa:  
 Tension was normal in all cases.  No orbit and adnexal pathology were 
found in our study.  
11. Optic neuritis and Systemic lupus erythematosus  
TABLE 11 
Optic neuritis  No of Patients Percentage 
Present  1 3.03 
Absent 32 96.97 
 
 
 
  
 
 
Various studies of optic neuropathy and systemic lupus erythematosus  
 
TABLE 12 
 
Studies  Years  No of 
patients  
Clinical Presentation  
Vitale et al,  1973 2 Optic neuritis  
Hackett et al,  1974 3 Optic neuritis  
Shepherd et al,  1974 2 Retrobulbar neuritis  
Kenkre  et al,  1978 1 Optic neuritis  
Kinney et al, 1979 1 Optic atropy 
Allen et al 1979 1 Retrobulbar neuritis  
2 Optic neuritis  
Lessel et al 1979 
1 Retrobulbar neuritis  
2 Optic neuritis  
1 Retrobulbar neuritis Smith et al 1982 
1 Optic atropy 
 
 
 
 
 
 
 
 
  
 
 
12. Retinal vasculitis and Systemic lupus erythematosus  
TABLE 13 
Patients Retinal haemorrhage Vasculitis Cotton wool spot Hard exudate 
1  1   
2 1 1 1  
3. 1 1   
4. 1   1 
 
4 patients had retinal vasculitis compared to 29 patients without changes. 
The incidence of retinal vasculitis is 12.2%. Vasculitis indicates vessel 
sheathing/ vessel narrowing/ tortusity. 3 patients had retinal haemorrhage, 3 
patients had vasculitis. Cotton wool spot and hard exudates were found in one 
patient.  
13. Comparison of Retinal vasculitis and Renal disease: 
TABLE 14  
Retinal vasculitis  
Renal disease  
Present  Absent  
Present  3 7 
Absent  1 22 
 
  
Out of 10 patients who had renal disease according to ACR criteria 3 patients 
had vasculitis compared to 7 patients without vasculitis. One patient had retinal 
vasculitis without renal disease where as the other 22 patients were normal.  
14. Comparison of Asian study & present study  
TABLE 15 
Asian study Present study 
Parameters  
Patients Percentage Patients Percentage
Total no of patients 70 - 33 - 
Males 4 6 2 6.06 
Females 66 94  31    93.9 
Mean age 32.9 - 27.20 - 
Symptomatic patients   5 7 3 9.09  
Ocular manifestation - - 21 63.63  
Abnormal schrimer 17 64.2 9 27.27 
Retinal vasculitis  9 12.85 4 12.12 
BCVA < 6/12 7 10 4 12.12 
Tension 2 2.8 - - 
Uveitis - - 1 3.03 
Keratitis - - 4 12.12 
 
  
DISCUSSION 
This study was conducted in Government Rajaji Hospital during the 
period January 2004- 2006. 33 patients who were diagnosed as systemic lupus 
erythematosus by ARA criteria were analysed for ocular manifestation.  
The youngest female reported was 11 years of age and oldest female was 
above 45 years. Out of 33 patients 21.2% were in the age group of 11- 20 years 
and 54.5% were in the age group of 21-30 years.  21.2% were in the age group 
of 30-40 years.   
According to Quan Dong Nguyen and C. Stephen foster in his study, 
“Systemic lupus erythematosus and Eye” has stated, “90% of systemic lupus 
erythematosus patients are woman with usual age of onset between the ages 15-
45 years”. In this study, only 2 patients were under 15 years 1 patient were over 
40 years. Most of the patients (93.94%) were in the age group of 15-45 years. 
Applying statistical analysis by proportion test it was inferred that age factor 
does not influence ocular manifestation. (i.e) Incidence of abnormal ocular 
manifestation is not due to age factor (p> 0.05) 
 There were 31 females and 2 males in this study. This result was similar 
to the study by YAPEY, Au Eong KG Fong KY, Howe HS, Boev ML, Cheah 
WM, Feng PH were they have quoted and incidence of  94% females and 4% 
  
males. Hence systemic lupus erythematosus  is common in female of child 
bearing  age group (15-45) years.  
 Ocular manifestations were found in 63.63% of study group. This 
stresses the importance of ocular manifestation in systemic lupus 
erythematosus. In the study by Peggy Frith and coworkers they have stated, 
“overall nearly half the patients had signs which could have been related to the 
underlying systemic lupus erythematosus.  In a study done in children (ie) 
Ocular manifestation of systemic lupus erythematosus in children by Al-
Mayouf SM, Al-Hemidam A1. They have quoted an incidence of 
34.6%(18patients). Compared with children adults have higher incidence of 
manifestation.  
 Out of 33 patients only 3(9.09%) patients complained of ocular 
symptoms. 2 patients had complaints of decreased vision and irritation and one 
patient complained of floaters. The rest 30 (90.9%) patients were 
asymptomatic. In the study Peggy Frith, “twelve patients or two-thirds, reported 
ocular symptoms. Intermittent redness of one or both globes with moderate 
discomfort and no discharge was suggestive of recurrent episcleritis some had 
itching and remaining were asymptomatic. Present studies incidence correlated 
well with the study in Tang Tock Sen hospital by YAPEY, Au Eong KG Fong 
KY, Howe HS, Boev ML, Cheah WM, Feng PH in which 7% of patients were 
symptomatic on examination.  
  
   27.27% of patients had abnormal schrimer test. In the study by 
Tan Tock Sen hospital by YAPEY, Au Eong KG Fong KY, Howe HS, Boev 
ML, Cheah WM, Feng PH, out of 70 patients 45 patients had abnormal 
schrimer test. This accounted for 64.2%. Where as the incidence of abnormal 
schrimer in the study by Al Mayouf SM , AL Hemidan AI,  was found to 
be13%. 
 In a study by Peggy Firth, “External ocular finding in lupus 
erythematosus” the incidence of dry eye was 2 out of 11 patients and it 
accounted for 22%. Lastly the study by Steinberg AD et al, has quoted that “the 
most common ocular manifestation of systemic lupus erythematosus is 
keratoconjunctivitis  sicca, approximately  in 25% of patients. 
 Thus the incidence of abnormal schirmer and dry eye status varied in 
different studies. Probably the inclusion criteria for dry eye status and test 
reliability will account for the varied presentation. 
   4 (12.2%) patients of keratitis were found out of 33 patients. All the 4 
patients had punctate superficial epithelial erosion. All the 4 patients had 
inferior superficial punctate epithelial erosion. No case of interstitial keratitis 
and peripheral ulcerative keratitis were reported.  
Gold and his collegues have reported an 6.6% incidence of keratitis in 
systemic lupus erythematosus patients. Speath found in a study of systemic 
lupus erythematosus patients that 88% had superficial punctate kertatitis with 
  
fluorescein corneal staining. Schrimer test results were normal in these patients, 
and therefore the issues of whether the superficial punctate keratitis seen in 
patients with systemic lupus erythematosus is a always truly the result of sicca 
syndrome or in fact is secondary to corneal epithelial damage associated with 
lupus disease activity is unclear.  
In our present study, out of the 4 cases of keratitis, 3 patients had 
abnormal schrimer and one had normal schrimer. Out of 23 patients who had 
normal schrimer, only one case of keratitis was reported. Statistical analysis 
using proportion test infers that the incidence of abnormal schrimer is not 
related to the incidence of keratitis at 5% level of significance (ie) patient also 
exhibit punctate keratitis unrelated to dry eye status.  
 Uveitis is seen only in one (3.03%) patient, which resolved with steroids. 
Patients presented with keratic precipitates, flare, cells with fibrinous 
membrane at pupillary margin unilaterally. Reviewing the literature, one case of 
bilateral iridocyclitis reported by Al Mayouf SM, AL Hemidan in study “ocular 
manifestation of systemic lupus erythematosus in children”.  
In the study by Drosos AA, Petris CA, Petroutsos GM, Moutsopoulos 
HM, “Unusual eye manifestations in systemic lupus erythematosus patients”, 
they have stated that anterior uveitis is not an uncommon manifestation of 
systemic lupus erythematosus and physicians must be aware of it during the 
  
patient’s evaluation, since it can be treated without serious visual loss. Our case 
responded well with steroid and visual acuity improved. 
Visual acuity in systemic lupus erythematosus patients were generally 
good but only 4 patients had less than 6/12 Best Corrected Visual Acuity. Out 
of these 4, 3 patients had posterior subcapsular cataract and one had optic 
neuritis. Many patients had refractive errors.  
In the study by YAP EY and his collegues. Only seven patients had 
BCVA worse than 6/12 because of optic neuropathy (4eyes), posterior 
subcapsular cataract (4 eyes), retinal vasculitis (3 eyes) and one eye had Pthsis 
bulbi. Hence many patients had good visual acuity except for a few. He 
attributes post subcapsular cataract as a part of treatment sequalae for the 
patients who are on steroids. Yet vision-threatening complications can occur in 
systemic lupus erythematosus is well proven which if intervened at appropriate 
time will prevent serious visual loss.  
 Tension was normal in all cases in our study. 3 eyes of 2patients had 
raised intraocular tension in the study by YAPEY and his collegues. None had 
any orbit, eyelid lesion, extraocular modality disorder or a retrochiasmal 
disorder of vision.  
One patient had manifestation of disc edema with haemorrhage and 
vitreous opacities, diagnosed as optic neuritis. The visual acuity was 6/36 p. 
  
The incidence of optic neuritis was found to be 3.03% in our study. Al Mayouf 
SM, AL Hemidan, has quoted incidence of 5.7% of optic neuritis in children.  
Teoch SC, in a study “Neuro- ophthalmological manifestations of 
systemic lupus erythematosus in Asian patients” has stated that the most 
common manifestations were that of optic neuropathy and eye movement 
abnormalities. The outcome was variable ranging from complete recovery to 
optic atrophy with navigational visual acuity. Treatment was often empirical, 
although early treatment with corticosteroids has been tried with varying 
success.  
Thus it is clear form our cases, as well as form those in the literature, 
that, although optic neuropathy in systemic lupus erythematosus is caused by an 
ischemic process in virtually all instances, the clinical presentation is quite 
varied. It would thus appear that in virtually any patient, particularly young 
women, who develop any type of optic neuropathy, whether unilateral or 
bilateral, the possibility of systemic lupus erythematosus must be considered, 
and an appropriate history, examination, and serologic studies may be required.       
4 patients had retinal vasculitis compared to 29 patients without changes. 
The incidence of retinal vasculitis is 12.2%. Vasculitis indicates vessel 
sheathing/ vessel narrowing/ tortuosity. 3 patients had retinal haemorrhage, 3 
patients had vasculitis. Cotton wool spot and hard exudates were found in one 
patient. 
  
Retinopathy is one of the important, if not major, manifestation of 
systemic lupus erythematosus which develops with an incidence of 7%-26%. 
All the findings of retinopathy were considered to reflect vascular damage, such 
as vasculitis and thromboembolism. For instance, haemorrhages, which were 
seen in 3 patients, might have been caused by vasculitis, thromboembolism or 
hypertension.   Vasculitis or microembolism of the vessel walls or neural fibres, 
or both, resulting in the formation of cotton wool spots and hard exudates. An 
important finding characteristic of lupus retinopathy is thought to be vasculitis 
of the retinal capillaries associated with local microinfarction. Charles describes 
the diagnosis   of retinal vasculitis with perivascular exudates and patches of 
fluorescein leakage along vessels. Histological evidence of immune mediated 
vasculitis has also been reported in lupus retinopathy. On the other hand, ocular 
fundus is the only part of the human body where we can directly observe small 
vessels without injuring the tissue. This suggests that fundus examination 
should be carried out more often.  
The retinopathy in patients with systemic lupus erythematosus was 
associated with renal dysfunction, CNS lupus, all of which were more or less 
related to vascular disorders.  By applying statistical test (proportion test) in our 
study an inference has been made that the levels of abnormal Creatinine 
influences the changes in retinopathy in systemic lupus erythematosus. 
  
[p<0.01]. Lupus retinopathy may reflect systemic vascular damage, which may 
develop in association with vasculitis.  
Comparing Asian study and present study, all parameters were of the 
same incidence except the abnormal schrimer. It has been inferred by using 
Wilcoxon signed Rank Test that Asian studies and the present studies yield the 
similar results at 5% level of significance. Thus there is no racial discrimination 
in ocular manifestations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SUMMARY 
This clinical study was done at Department of ophthalmology Govt. Rajaji 
Hospital Madurai. 
 A total of 33 patients were examined and out of which 31 (93.9%) 
were females and 2 (6.06%) were males.  
 The mean age of manifestation of systemic lupus erythematosus were 
found to be range from 11 to 45 yrs – [27.20 yrs]   
 Ocular manifestations were found in 63.63 % of patients in systemic 
lupus erythematosus.  
 3 patients (9.09%) were symptomatic on examination.  
 9 (27.27%) patients had features of dry eye (abnormal schrimer, less 
than 10mm, tear break up time less than (10sec)  
 4 patients (12.12%) had punctate epithelial keratitis  
 Patients also exhibit punctate keratitis   unrelated to dry eye status.  
 One patient (3.03%) had unilateral anterior uveitis. 
 7 patients had worse than 6/12 Visual acuity (3 patients) Subcapsular 
cataracts, 2patients retinal vasculitis, 1 Optic neuritis, 1 episcleritis 
with refractive error.  
 Intraocular pressure was normal in all cases.  
 No eyelid lesion, orbital lesions were found  
  
 One patient (3.03%) had optic neuritis  
 Four patients (12.12%) had retinal vasculitis.  
 The patient with retinal vasculitis had higher levels of serum 
creatinine than patients without retinal vasculitis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
 Eye is a highly sensitive Barometer for the onset and reactivation of 
autoimmune phenomenon.  
 In this study the prevalence of ocular manifestation in systemic lupus 
erythematosus was 63.63%. This stresses the importance of ocular 
manifestation in systemic lupus erythematosus. Sight threatening 
complication can occur in systemic lupus erythematosus which if intervened 
at appropriate time will prevent serious visual loss. Patients with retinopathy 
in systemic lupus erythematosus had higher serum creatinine levels than 
patients without retinopathy.  
 Hence from these observations, ocular manifestation in systemic lupus 
erythematosus had led us to the belief that ocular inflammation should be 
added to the criteria for classification of systemic lupus erythematosus. Such 
inclusion may lead to better awareness of systemic lupus erythematosus 
ocular disease for the physician & may yield better outcome in diagnostic 
prognostic therapeutic ways for the patient.  
 
 
 
 
  
PROFORMA 
 
I. PATIENTS RECORD  
Name   Age   Sex   Male /Female:  
Address     I.P/O.P – No  
II. Complaint:  
Laterality    Right eye Left eye Both eye 
 
Symptoms:   Defective vision     
   Foreign body sensation/ Irritation     
   Pain       
   Floaters       
   Duration  
   Onset 
Severity 
Course 
   Previous attack  
SYSTEMIC HISTORY  
General  Fever/malaise / Loss of Weight/Loss of Appetite   
Skin  Rashes / nodules / utricaria / edema / raynaud 
phenomenon/ alopecia / ulcers  
Joints Arthritis / Arthralgia  
  
Neurological   headache / seizures / psychoses  
Renal  edema of legs / puffiness of face / polyuria / oliguria  
 
H/O INTAKE OF DURGS  
Treatment history   On steroid     
   Not on steroid    
   Anti metabolites    
OCULAR EXAMINATION  
1. Eye brows   Madrosis  
2. Eye lids    Madrosis  
   Discoid lupus  
3. Tear film    Tear film height/Tear break up time/  
  Schrimer test 
4. Conjunctiva   Congestion / pterygium / nodule  
5. Cornea    keratitis (superficial punctate keratitis /ulcer/  
interstitial keratitis)  
6. Corneal sensation   present / absent   
7. Anterior chamber  shallow/ Normal depth / flare / cells  
8. Iris    Iridocyclitis (Acute /chronic)  
   synechiae  
   membrane  
  
 
9. Pupil    size / shape /  
reaction    direct   
     Indirect  
  Relative afferent pupillary  defect 
10. Lens    Clear  
   Immature cataract  
   Posterior sub capsular cataract 
   Mature cataract   
   Aphakia  
   Intra Ocular Lens 
11. Best corrected Visual Acuity Right Eye   
     Left Eye 
12. Staining of cornea  
13. Intra Ocular Pressure 
14. Fields  
15. Colour Vision   
16. Refraction    Objective 
    Subjective 
 
 
  
17. Fundus  
Direct ophthalmoscope  
 Indirect ophthalmoscope  
19. Orbit and adnexa  
 
Diagnosis  
Lab investigations     
1. Total Count  
Differential Count 
Erythrocyte Sedimentation Rate  
 
2. Urine  Albumin   
Sugar 
Deposits 
3. Haemoglobulin  
Red Blood Cell Count  
Platelets Count  
Bleeding Time / Clotting Time     
4. Serum Creatinine  
Blood Urea  
Urine Protein  
  
5. Peripheral Smear  
6. Anti double stranded DNA 
7. (LE) Cell  
Treatment  
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MACULOPAPULAR RASH WITH MUCOSAL 
ULCERATIONS 
 
 
 
 
 
 
 
PATHOGENESIS 
 
 
 
 
 
 
THE THICK RED ARROW DEMONSTRATES 
SYNOVIAL THICKENING AND SUBCUTANEOUS 
ERYTHEMA IN A PATIENT WITH SLE. THE THIN 
BLACK AREAS SHOW TWO SMALL SUBCUTANEOUS 
INFARCTS. 
 
 
 
 
 
 
 
 
EPISCLERITIS 
 
 
 
 
 
 
 
SCLERITIS 
 
 
 
 
 
 
 
 
 
 
 
UVEITIS – POSTERIOR SYNECHIAE WITH 
FESTOONED PUPIL 
 
 
 
 
 
RETINAL VESSEL SHEATHING 
 
 
 
 
 
 
 
 
 
 
 
DISC EDEMA WITH MULTIPLE COTTON WOOL 
SPOTS 
 
 
 
 
 
 
FUNDUS FLUORESCEIN ANGIOGRAPHY 
DYE LEAKAGE SEEN 
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1 Ocular Manifestaton Absent Present 
2 Eyebrows/Lids Normal Abnormal
3 Conjunctiva Normal Congestion
4 Tear Film  Level Normal Abnormal
5 Breakup time Normal Abnormal
6 Schrimer Strip Normal Abnormal
7 Sclera Normal Scleritis
8 Cornea Normal Keratitis
9 Anterior Chamber Normal Flare/ cells
10 Iris Normal Iritis
11 Pupil size Normal  Miotic  Dilated
Reaction a - Present b - absent 
12 Lens Clear PCC Immature Cataract Mature Cataract Aphakia Intra Ocular Lens
13 Tension Normal Raised Decreased
14 Fields & Colour Visio Normal Abnormal
15 Vitreous Normal Vitritis
16 Disc Normal Edematous atropy
17 Macular Normal Abnormal
18 Vessels Normal Narrowed Venis dilated Sheathing
19 Background Retina Normal Haemorrages Cotton wool spots Hard exudates 
20 Renal Disease Absent Present
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